Otonomy staggered by an ugly PhIII failure for lead pipeline drug
A little more than two years ago, San Diego-based Otonomy $OTIC tried to explain why it was taking its failed Phase IIb drug for a disease called Ménière’s disease — with frequent episodes of vertigo — into a pivotal study with two Phase III trials.
While Otividex flunked the primary endpoint in reducing vertigo frequency, it did just barely hit a mark for reducing counted vertigo days at month 3. So they changed up the endpoints to go after vertigo days and went into Phase III.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.